ConductScience.org, home

Trial · NCT03100344

Adverse event totals12

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityPlacebo056
Total, all-cause mortalityNemolizumab (10 mg)155
Total, all-cause mortalityNemolizumab (30 mg)057
Total, all-cause mortalityNemolizumab (90 mg)057
Total, other adverse eventsPlacebo4356
Total, other adverse eventsNemolizumab (10 mg)4755
Total, other adverse eventsNemolizumab (30 mg)4757
Total, other adverse eventsNemolizumab (90 mg)4757
Total, serious adverse eventsPlacebo156
Total, serious adverse eventsNemolizumab (10 mg)355
Total, serious adverse eventsNemolizumab (30 mg)257
Total, serious adverse eventsNemolizumab (90 mg)257

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03100344/event-totals